QPPV.COM KNOWLEDGE ASSESSMENT

Knowledge Assessment: EudraVigilance Data for MAHs—ICSR Monitoring and Safety Use

Test your understanding of the concepts covered by EudraVigilance Data for MAHs: ICSR Monitoring and Safety Use.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Which classification correctly describes the three categories used to characterize EudraVigilance activities?

Mandatory means required by applicable requirements; recommended means specifically encouraged; useful means scientifically or operationally valuable without being a blanket mandate Mandatory means preferred by the QPPV; recommended means required by law; useful means prohibited unless approved Mandatory, recommended and useful are interchangeable terms for internal procedures Useful activities are automatically mandatory when data are available

Question 2 of 10 A potential safety issue has been identified through the applicable signal-monitoring process. Which approach is most appropriate for validation?

Rely solely on one numerical output from EVDAS Use the applicable EudraVigilance analytical information and relevant individual cases, consider the broader clinical evidence and document the rationale Treat the issue as validated automatically because it appears in EudraVigilance Exclude case-level information to avoid introducing clinical judgment

Question 3 of 10 What conclusion follows from the distinction between monitoring and downloading?

A monitoring obligation automatically requires a permanent local copy of every EudraVigilance record An MAH may never retrieve EudraVigilance information Monitoring can be fulfilled only by using printed line listings The required review process does not automatically imply downloading and permanently storing all available records

Question 4 of 10 Which workflow best reflects a controlled ICSR monitoring process?

Download data, submit a PSUR, and archive the download Review relevant information, identify cases, search the internal database, assess new or duplicate status, take case action and document completion Review only cases associated with already validated signals Wait for an inspector to request EudraVigilance evidence before reviewing cases

Question 5 of 10 An EudraVigilance report appears to match an existing internal case but includes new laboratory findings. What is the most appropriate interpretation?

It must always be treated as a completely new case It should be discarded because the core case is already known It should be assessed as possible additional or follow-up information and incorporated where clinically relevant It should be counted twice to ensure the laboratory findings are visible

Question 6 of 10 Why should an MAH reassess its procedures when EudraVigilance functionality or technical documentation changes?

Because any system change automatically changes every legal obligation Because changes may affect access, retrieval, monitoring frequency, reports, analytical workflows, training and vendor processes Because current EMA documentation is less relevant than historical procedures Because technical changes eliminate the need for documented controls

Question 7 of 10 Why should procedures identify the source supporting each EudraVigilance requirement?

To ensure that all activities are performed by the same person To distinguish binding requirements from recommendations or internal good practice and support defensible governance To avoid documenting monitoring outputs To make historical EMA screenshots the controlling source

Question 8 of 10 An SOP states that all EudraVigilance datasets must be downloaded for every PSUR, signal review and aggregate analysis. What is the principal concern with this wording?

It may understate the importance of EudraVigilance It creates an unsupported blanket mandate and may generate unnecessary processing, storage and reconciliation work It prevents the MAH from using any EudraVigilance information It guarantees that the procedure will remain valid when system requirements change

Question 9 of 10 An MAH assumes that its spontaneous-reporting system contains every relevant case and therefore stops monitoring applicable EudraVigilance information. What is the main risk?

Unnecessary duplication of safety information Failure to identify relevant NCA-originated cases or additional information, creating a potential pharmacovigilance control gap Excessive use of line listings Overclassification of useful analyses as mandatory

Question 10 of 10 Which record would provide the strongest inspection evidence for routine EudraVigilance monitoring?

A retrospective statement from the QPPV that monitoring was probably performed A contemporaneous record showing the information reviewed, review date, responsible person, cases assessed and resulting actions A list of all products in the company's portfolio A screenshot of an outdated EudraVigilance user manual

Knowledge Assessment: EudraVigilance Data for MAHs—ICSR Monitoring and Safety Use

Cookie Settings